

# Development and Validation of a UPLC Method for the Determination of Albendazole Residues on Pharmaceutical Manufacturing Equipment Surfaces

R. S. Chandan, M. Vasudevan, Deecaraman, B. M. Gurupadayya

**Abstract**—In Pharmaceutical industries, it is very important to remove drug residues from the equipment and areas used. The cleaning procedure must be validated, so special attention must be devoted to the methods used for analysis of trace amounts of drugs. A rapid, sensitive and specific reverse phase ultra performance liquid chromatographic (UPLC) method was developed for the quantitative determination of Albendazole in cleaning validation swab samples. The method was validated using an ACQUITY HSS C<sub>18</sub>, 50 x 2.1mm, 1.8 $\mu$  column with a isocratic mobile phase containing a mixture of 1.36g of Potassium dihydrogenphosphate in 1000mL MilliQ water, 2mL of triethylamine and pH adjusted to 2.3  $\pm$  0.05 with ortho-phosphoric acid, Acetonitrile and Methanol (50:40:10 v/v). The flow rate of the mobile phase was 0.5 mL min<sup>-1</sup> with a column temperature of 35<sup>o</sup>C and detection wavelength at 254nm using PDA detector. The injection volume was 2 $\mu$ L. Cotton swabs, moisten with acetonitrile were used to remove any residue of drug from stainless steel, teflon, rubber and silicon plates which mimic the production equipment surface and the mean extraction-recovery was found to be 91.8. The selected chromatographic condition was found to effectively elute Albendazole with retention time of 0.67min. The proposed method was found to be linear over the range of 0.2 to 150 $\mu$ g/mL and correlation coefficient obtained is 0.9992. The proposed method was found to be accurate, precise, reproducible and specific and it can also be used for routine quality control analysis of these drugs in biological samples either alone or in combined pharmaceutical dosage forms.

**Keywords**—Cleaning validation, Albendazole, residues, swab analysis, UPLC.

## I. INTRODUCTION

MEDICINES are primarily intended to promote good health; however, when residual compounds remain in the manufacturing process, potential for side effects from toxic levels of contaminants increases. Cross-contamination with extraneous residues of any kind presents a safety risk to patients consuming any drug product. For this reason, the

Chandan R S is with Dept. of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS University, Mysore- 570015, India (phone: 0091 9900622911; fax: 0821 2548359; e-mail: chandan2211@rediffmail.com).

M Vasudevan is with Department of Industrial Biotechnology, Dr. M.G.R Educational and Research Institute, Dr. M. G. R. University, Maduravoyal, Chennai 600 009, India (phone: 0091 8939902904, e-mail: vasu2904@yahoo.com).

Deecaraman is with Department of Industrial Biotechnology, Dr. M.G.R Educational and Research Institute, Dr. M. G. R. University, Maduravoyal, Chennai 600 009, India, (phone: 0091 9840304749, e-mail: deecaraman@yahoo.com).

B M Gurupadayya is with Dept. of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS University, Mysore- 570015, India (phone: 0091 9242886136; fax: 0821 2548359; e-mail: bm\_guru2004@yahoo.com).

FDA has recognized, with greater importance, that effective cleaning and sanitizing protocols are a proactive measure in preventing cross-contamination in pharmaceutical and cosmetic production.

As 21 CFR sect 211.67 states [1], "Equipment and utensils shall be cleaned, maintained, and sanitized at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements." The objective of the cleaning validation [2] is to verify the effectiveness of the cleaning procedure for removal of product residues, degradation products, preservatives, excipients and/or cleaning agents so that the analytical monitoring may be reduced to a minimum in the routine phase.

Albendazole is chemically described as Methyl [5-(propylsulphonyl)-1H-benzimidazol-2-yl] carbamate (Fig. 1). Literature survey reveals various analytical methods for the determination of Albendazole by HPLC [3]-[6].




Fig. 1 Albendazole

## II. MATERIALS AND METHODS

### A. Chromatographic Conditions

WATERS Acquity UPLC with PDA detector and Empower 2.0 software was employed for present study. The chromatography determination performed by using ACQUITY HSS C<sub>18</sub>, 50 x 2.1mm, 1.8 $\mu$  column with a isocratic mobile phase containing a mixture of 1.36g of Potassium dihydrogenphosphate in 1000mL MilliQ water, 2mL of triethylamine and pH adjusted to 2.3  $\pm$  0.05 with ortho-phosphoric acid, Acetonitrile and Methanol (50:40:10 v/v). The flow rate of the mobile phase was 0.5mL min<sup>-1</sup> with a column temperature of 35<sup>o</sup>C and detection wavelength at 254nm using PDA detector. The injection volume was 2 $\mu$ L.

### B. Preparation of Stock Solutions

#### 1. Preparation of Standard Solution

The 1000  $\mu$ g/ml of Albendazole were prepared using Acetonitrile. The subsequent dilutions of this solution were

made with Acetonitrile to get concentration range of 0.2 to 150µg/mL. The standard calibration curve for Albendazole (Fig. 4) are constructed with the series of working standards taking the concentration on X-axis and their respective peak areas on Y- axis.

2. Preparation of Sample Solution

The Cleaned swab was taken and sampling was done according to sampling procedure on the surface of the equipment where sampling has to be done (Fig. 2). The sampled swab was dipped into 10 ml of diluent and was sonicated for about 5 minutes. The solution was filtered through 0.2µm Nylon filter and the sample solution was analyzed using HPLC. The Standard chromatogram of Albendazole was shown in Fig. 3.




Fig. 2 Structure of Swabbing Pattern

3. Method Validation

The method was validated in accordance with USP & International Conference of Harmonization (ICH) Guidelines [7].




Fig. 3 Standard chromatogram of Albendazole

III. RESULTS AND DISCUSSION

A. System Suitability

System suitability tests are used to verify the reproducibility of the chromatographic system.

TABLE I  
SYSTEM SUITABILITY

| Sl. No. | System Suitability Parameter  | Observations | Proposed Acceptance Criteria |
|---------|---|--------------|------------------------------|
| 1       | % RSD for six replicate injections of analyte peak in standard solution | 0.5          | Should be not more than 5.0% |
| 2       | Tailing factor for analyte peak in standard solution                    | 1.2          | Should be not more than 2.0  |
| 3       | USP plate count for analyte peak in standard solution                   | 1214         | Should be not less than 1000 |

B. Limit of Detection and Limit of Quantification

TABLE II

PEAK RESULTS FOR LIMIT OF DETECTION AND LIMIT OF QUANTIFICATION

| Concentration | Area response |
|---------------|---------------|
| 0.05          | 473           |
| 0.1           | 637           |
| 0.2           | 1274          |
| 0.3           | 1837          |
| 0.4           | 2573          |
| 0.5           | 3427          |
| 0.6           | 4279          |
| 0.7           | 5014          |
| 0.8           | 5627          |
| 1.0           | 7194          |
| Slope         | 6571.27       |
| RSD           | 126.31        |
| LOD           | 0.06          |
| LOQ           | 0.19          |

range of 0.2µg/ml to 150µg/ml and Correlation coefficient obtained is 0.9992.




Fig. 4 Calibration graph of Albendazole

C. Linearity and Range

The method was found to be linear in the concentration

TABLE III  
PEAK RESULTS FOR LINEARITY

| Linearity level Conc. (%) | Area Response |
|---------------------------|---------------|
| LOQ                       | 1274          |
| 20                        | 13860         |
| 40                        | 28125         |
| 60                        | 42345         |
| 80                        | 57045         |
| 90                        | 63482         |
| 100                       | 70556         |
| 120                       | 84583         |
| 140                       | 97945         |
| 150                       | 104852        |

*D. Precision at Lower and Higher Concentrations*

This was carried out to check reproducibility of results at lower level and higher levels of linearity.

TABLE IV  
PEAK RESULTS FOR PRECISION AT LOWER AND HIGHER CONCENTRATIONS

| Sl. No. | Area Responses    |                     |
|---------|-------------------|---------------------|
|         | Lower level (LOQ) | Higher level (150%) |
| 1       | 1104              | 104852              |
| 2       | 1034              | 103503              |
| 3       | 1113              | 104282              |
| 4       | 1062              | 106038              |
| 5       | 1082              | 103738              |
| 6       | 1192              | 104292              |
| Average | 1097              | 104450              |
| SD      | 54.30             | 909.9               |
| % RSD   | 4.9               | 0.8                 |

*E. Precision*

1. System Precision

TABLE V  
PEAK RESULTS FOR SYSTEM PRECISION

| Injection No | Area Response |
|--------------|---------------|
| 1            | 70458         |
| 2            | 70748         |
| 3            | 69703         |
| 4            | 70395         |
| 5            | 70030         |
| 6            | 70194         |
| 7            | 68028         |
| 8            | 69309         |
| 9            | 69308         |
| 10           | 70295         |
| Average      | 69847         |
| SD           | 791.7         |
| % RSD        | 1.2           |

2. Method Precision

Method precision indicates whether a method is giving consistent results for a single material.

TABLE VI  
PEAK RESULTS FOR METHOD PRECISION

| Spl. No. | Inj. | RT (min) | Area    |
|----------|------|----------|---------|
| 1        | 1    | 0.70     | 69586   |
|          | 2    | 0.70     | 69384   |
| 2        | 1    | 0.71     | 70194   |
|          | 2    | 0.72     | 69930   |
| 3        | 1    | 0.70     | 69294   |
|          | 2    | 0.70     | 69248   |
| 4        | 1    | 0.69     | 68295   |
|          | 2    | 0.71     | 68943   |
| 5        | 1    | 0.71     | 69038   |
|          | 2    | 0.72     | 68327   |
| 6        | 1    | 0.70     | 67285   |
|          | 2    | 0.71     | 67194   |
|          | Mean |          | 68893.6 |
|          | SD   |          | 959.8   |
|          | %RSD |          | 1.4     |

*F. Specificity*

On the basis of these chromatograms we can say that there is no interference of blank swab (Fig. 5) and placebo (Fig. 6).




Fig. 5 Chromatogram of blank




Fig. 6 Chromatogram of placebo

*G. Ruggedness*

Ruggedness is a measure of reproducibility of test results

under the variation in conditions normally expected from laboratory to laboratory and from analyst to analyst.

TABLE VII  
RUGGEDNESS RESULTS

| Sr. No.         | Albendazole in ppm |        |         |        |
|-----------------|--------------------|--------|---------|--------|
|                 | SET I              | SET II | SET III | SET IV |
| 1               | 9.8                | 9.9    | 10.0    | 9.9    |
| 2               | 9.9                | 10.1   | 9.9     | 9.9    |
| 3               | 9.8                | 10.1   | 9.9     | 9.8    |
| 4               | 9.9                | 10.0   | 10.1    | 10.0   |
| 5               | 9.9                | 9.9    | 10.1    | 9.9    |
| 6               | 9.9                | 9.9    | 10.0    | 10.1   |
| Average         | 9.9                | 9.9    | 10      | 9.9    |
| SD              | 0.05               | 0.09   | 0.08    | 0.10   |
| % RSD           | 0.5                | 0.9    | 0.9     | 1.0    |
| Overall Average | 9.9                |        |         |        |
| Overall % RSD   | 0.8                |        |         |        |

SET – I : Method precision

SET – II : Variability due to HPLC system

SET – III : Variability due to HPLC column

SET – IV: Variability due to analyst

#### H. Accuracy

TABLE VIII  
RECOVERY RESULT OF ALBENDAZOLE

| Recovery level   | % Recovery of Albendazole |              |              |               |  | Average recovery (Particular level) | % RSD (Particular level) |
|------------------|---------------------------|--------------|--------------|---------------|--|-------------------------------------|--------------------------|
|                  | Stainless steel plate     | Teflon plate | Rubber plate | Silicon plate |  |                                     |                          |
| LOQ              | 86.4                      | 92.6         | 88.5         | 86.9          |  | 88.6                                | 3.17                     |
| 50%              | 90.2                      | 92.2         | 90.4         | 93.4          |  | 91.5                                | 1.66                     |
| 100%             | 90.7                      | 96.2         | 93.6         | 87.1          |  | 92.4                                | 3.4                      |
| 150%             | 89.3                      | 95.4         | 90.2         | 94.2          |  | 92.3                                | 3.2                      |
| Average Recovery | 89.15                     | 94.1         | 90.67        | 90.4          |  | Overall Recovery<br>91.2            |                          |
| % RSD            | 2.15                      | 2.12         | 2.34         | 4.35          |  | Overall RSD<br>2.8                  |                          |

#### I. Robustness

The robustness of an analytical procedure is a measure of its capacity to remain unaffected by small, but deliberate variations in method parameters and provides an indication of its reliability during normal usage.

#### J. Solution Stability

The standard and sample solutions of Albendazole were found to be stable for 36 hrs and no additional peak was observed in the solution.

TABLE IX  
PEAK RESULTS FOR ROBUSTNESS

| Parameter  | Condition   | USP tailing | USP Plate Count |
|--|-------------|-------------|-----------------|
| Flow rate by<br>± 10%                                | 0.4 ml      | 1.6         | 1245            |
|  | 0.5 ml      | 1.2         | 1214            |
|  | 0.6 ml      | 1.2         | 1175            |
| Column Oven<br>temperature by<br>± 5°C               | 30°C        | 1.3         | 1032            |
|  | 35°C        | 1.2         | 1214            |
|  | 40°C        | 1.2         | 1474            |
| pH of Buffer<br>solution by ±<br>0.2 units           | 2.1         | 1.1         | 1495            |
|  | 2.3         | 1.2         | 1214            |
|  | 2.5         | 1.7         | 954             |
| Wavelength of<br>analysis ± 5nm                      | - nm        | 1.5         | 1204            |
|  | * nm        | 1.2         | 1214            |
|  | + nm        | 1.2         | 1213            |
| Organic<br>composition of<br>mobile phase<br>by ± 5% | 525:385:90  | 1.4         | 896             |
|  | 500:400:100 | 1.2         | 1214            |
|  | 475:415:110 | 1.1         | 1423            |

\*Wavelength selected for specific drug

TABLE X  
SOLUTION STABILITY FOR STANDARD AND SAMPLE SOLUTION

| Time (Hrs.) | Standard solution |       |              |              | Sample solution |       |              |              |
|-------------|-------------------|-------|--------------|--------------|-----------------|-------|--------------|--------------|
|             | Inj.1             | Inj.2 | Average area | % Difference | Inj.1           | Inj.2 | Average area | % Difference |
| Initial     | 69765             | 69675 | 69720        | NA           | 67884           | 67452 | 67668        | NA           |
| 6hrs        | 70175             | 70532 | 70354        | 0.9          | 68395           | 68792 | 68594        | 1.4          |
| 12hrs       | 70456             | 70246 | 70351        | 0.9          | 68030           | 68146 | 68088        | 0.6          |
| 20hrs       | 70987             | 70257 | 70622        | 1.3          | 68304           | 68394 | 68349        | 1.0          |
| 26hrs       | 70975             | 70794 | 70885        | 1.7          | 68013           | 68359 | 68186        | 0.8          |
| 30hrs       | 71492             | 70137 | 70815        | 1.6          | 68363           | 68624 | 68494        | 1.2          |
| 36hrs       | 70345             | 71359 | 70852        | 1.6          | 68674           | 68954 | 68814        | 1.7          |

## K. Filter Interference

TABLE XI  
FILTER INTERFERENCE FOR STANDARD AND SAMPLE SOLUTION

| For Standard      |            |              | For Sample        |             |              |
|-------------------|------------|--------------|-------------------|-------------|--------------|
| Filtration Method | Unfiltered | 0.2µm SY25NN | Filtration Method | Centrifuged | 0.2µm SY25NN |
| Area (Inj. 1)     | 70839      | 70193        | Area (Inj. 1)     | 68959       | 68795        |
| Area (Inj. 2)     | 71385      | 70493        | Area (Inj. 2)     | 69894       | 68498        |
| Avg. Area         | 71112      | 70343        | Avg. Area         | 69427       | 68647        |
| % Difference      |            | 1.1          | % Difference      |             | 1.1          |

## IV. CONCLUSION

Although various methods have been reported for the estimation of Albendazole it was found that the methods proposed were time taking and results in delay of batch clearance for the next production batch to start. The cleaning validation procedures for Albendazole with UPLC were not reported. Hence an attempt has been made to develop simple and accurate methods for the estimation of Albendazole by UPLC.

Results of analysis of the swab samples revealed that the proposed method is suitable for their analysis with no interference from the swab and recovery is found to be acceptable. The method was found to be linear, precise, accurate, specific and all proved to be sensitive, convenient and effective for the determination of Albendazole in swab samples.

## ACKNOWLEDGMENT

Authors are highly thankful to Dr. H. G. Shivakumar, Principal, JSS College of Pharmacy, JSS University, Mysore, for his constant encouragement and support and JSS University, Mysore, for providing the required infrastructure to carry out the research activities.

## REFERENCES

- [1] FDA, Guide to Inspections of Validation of Cleaning Processes, 1993.
- [2] Health Canada, Health Products and Food Branch Inspectorate, GMP - Cleaning Validation Guidelines, Jan, 2000: 3-10.
- [3] Kullai Reddy Ulavapalli, J. Sriramulu1, Useni Reddy Mallu Viswanath Reddy Pyreddy and Varaprasad Bobbarala. RP-HPLC Method for Simultaneous Estimation of Levamisole, Mebendazole and Albendazole in Pharmaceutical Products. Indian Journal of Novel Drug delivery, 2011; 3(2):134-142.
- [4] Juan Jose Garciaa, Francisco Bola's-Fernandeza, Juan Jose Torrado, Quantitative determination of albendazole and its main metabolites in plasma, Journal of Chromatography B, 1999; 723: 265-271.
- [5] Shu-chusu, chin-linchang, pi-chiouchang and shin-shouchou, Simultaneous determination of albendazole, thiabendazole, mebendazole and their metabolites in livestock by high performance liquid

chromatography, Journal of Food and Drug Analysis, 2003; 11(4): 307-319.

- [6] Anil Waldia, Shubash Gupta, RoshanIssarani & Badri P Nagori, Validated liquid chromatographic method for the simultaneous estimation of Albendazole and ivermectin in the tablet dosage form, Indian Journal of hemial Technology, 2008; 15:616-620.
- [7] International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Text and Methodology, ICH - Q2(R1), Geneva 2005.